Group 1 - The core viewpoint of the article is that AcoArt Canna, a drug-coated balloon catheter developed by the company, has received registration approval from the National Medical Products Administration of China, which is expected to enhance the company's market position [1] - The stock price of the company increased by 4.63%, reaching HKD 11.97, with a trading volume of HKD 6.25 million [1] - AcoArt Canna is indicated for the treatment of primary coronary artery bifurcation lesions with a vessel diameter between 2.0mm and 4.0mm [1] Group 2 - Clinical trial results demonstrated the effectiveness and safety of AcoArt Canna, with a target lesion branch vessel diameter stenosis rate (DS%) of 30.52% at 9 months post-operation, compared to 33.46% for the control group using a paclitaxel-coated balloon, showing no statistical difference [1] - Safety data analysis indicated that the trial group did not present abnormal risks or events compared to the control group [1] - The company plans to initiate marketing activities in China at an appropriate time [1]
先瑞达医疗-B涨超4% 近日西罗莫司药物涂层冠脉球囊扩张导管AcoArt Canna 注册获批